From the outset, management of ZabBio have defined the role of the firm as that of developing monoclonal antibody-based products to address unmet needs in infectious diseases and in reproductive health. Consistent with that latter area of focus, in late 2019, ZabBio was funded by the Bill andMelinda Gates Foundation to support the conduct of pre-clinical studies of a potential novel, non-hormonal female contraceptive. The firm produce mAb's for a variety of projects within N. Benthamiana plant expression system: mainly for human diseases, reproductive health, and conditions that are a threat to bio-defense and global health
